GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » YoY EBITDA Growth

Shanghai Bio-heart Biological Technology Co (HKSE:02185) YoY EBITDA Growth : 71.08% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Shanghai Bio-heart Biological Technology Co's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 71.08%.

Shanghai Bio-heart Biological Technology Co's EBITDA per Share for the six months ended in Jun. 2024 was HK$-0.11.

Shanghai Bio-heart Biological Technology Co YoY EBITDA Growth Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co YoY EBITDA Growth Chart

Shanghai Bio-heart Biological Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- -2,102.67 -33.05 56.41 21.71

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.52 46.32 27.17 19.83 71.08

Shanghai Bio-heart Biological Technology Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Shanghai Bio-heart Biological Technology Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.75--0.958)/ | -0.958 |
=21.71 %

Shanghai Bio-heart Biological Technology Co's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.107--0.37)/ | -0.37 |
=71.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Bio-heart Biological Technology Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Bio-heart Biological Technology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » YoY EBITDA Growth
Comparable Companies
HKSE:06998 HKSE:02126 HKSE:01228 HKSE:02197 HKSE:06996 HKSE:03681 HKSE:00690 HKSE:02142 HKSE:09939 HKSE:08158 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Website
http://www.bio-heart.com
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Executives
Wang Nengguang 2201 Interest of corporation controlled by you
Magic Grace Limited 2101 Beneficial owner
Loft Success Investments Limited 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p. 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited 2201 Interest of corporation controlled by you
Lc Fund Gp Limited 2201 Interest of corporation controlled by you
Great Unity Fund I, L.p. 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
Proud Solar Limited 2201 Interest of corporation controlled by you
Right Lane Limited 2201 Interest of corporation controlled by you
Sk China Company Limited 2201 Interest of corporation controlled by you
Union Season Holdings Limited 2201 Interest of corporation controlled by you
Zhu Linan 2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines